(Q39365303)

11 September 2017

title

Once-daily fexofenadine treatment for chronic idiopathic urticaria: a multicenter, randomized, double-blind, placebo-controlled study (English)

1 reference

multicenter clinical trial

11 September 2017

0 references

0 references

1 reference

1 reference

Allen P Kaplan

1

1 reference

11 September 2017

Sheldon L Spector

2

1 reference

11 September 2017

Suzanne Meeves

3

1 reference

11 September 2017

Yuning Liao

4

1 reference

11 September 2017

Santosh T Varghese

5

1 reference

11 September 2017

George Georges

6

1 reference

11 September 2017

publication date

1 June 2005

1 reference

Annals of Allergy, Asthma & Immunology

11 September 2017

published in

1 reference

11 September 2017

volume

94

1 reference

11 September 2017

issue

6

1 reference

11 September 2017

page(s)

662-669

1 reference

The urticarias. Current concepts in pathogenesis and treatment

11 September 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Prevalence and functional role of anti-IgE autoantibodies in urticarial syndromes

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Mechanisms of autoimmune activation of basophils in chronic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Chronic idiopathic urticaria treatment

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Safety of second generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

New insights into the second generation antihistamines

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

1 reference

7 January 2021

A double-blind, placebo-controlled trial of fexofenadine HCl in the treatment of chronic idiopathic urticaria.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Fexofenadine HCl is safe and effective for treatment of chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Review of fexofenadine in the treatment of chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Clinical practice. Chronic urticaria and angioedema

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

1 reference

7 January 2021

Treatment of patients with chronic idiopathic urticaria

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Cetirizine and astemizole therapy for chronic idiopathic urticaria: a double-blind, placebo-controlled, comparative trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Once-daily desloratadine improves the signs and symptoms of chronic idiopathic urticaria: a randomized, double-blind, placebo-controlled study

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Efficacy and safety of desloratadine 5 mg once daily in the treatment of chronic idiopathic urticaria: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

First do no harm: managing antihistamine impairment in patients with allergic rhinitis.

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Antihistamines: models to assess sedative properties, assessment of sedation, safety and other side-effects

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Sedation and antihistamines: a review of inter-drug differences using proportional impairment ratios

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

Sedation with "non-sedating" antihistamines: four prescription-event monitoring studies in general practice

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

The NHS: last act of a Greek tragedy? Government that puts money into redressing inequalities is worthy of support

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2961325-7

7 January 2021

10.1016/S1081-1206(10)61325-7

Identifiers

DOI

1 reference

11 September 2017

1 reference